Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Current Management of In-Stent Restenosis

  • Her, Ae-Young (Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Shin, Eun-Seok (Division of Cardiology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine)
  • Received : 2018.04.02
  • Accepted : 2018.04.10
  • Published : 2018.05.31
⟨ Previous Next ⟩

Abstract

Despite the advent of the drug-eluting stents (DES) and improved stent design, in-stent restenosis (ISR) remains a challenging problem. The currently available options for treatment of ISR include angioplasty alone, repeat stenting with DES or drug-coated balloons. Several recent studies have compared the available options for treating ISR in an attempt to identify the preferred therapeutic strategy. In this review, we will discuss the currently available therapeutic strategies for the management of patients with ISR and the evidence supporting their use.

Keywords

References

  1. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23. https://doi.org/10.1001/jama.294.10.1215
  2. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8. https://doi.org/10.1161/01.CIR.100.18.1872
  3. Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation 1993;88:1310-23. https://doi.org/10.1161/01.CIR.88.3.1310
  4. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-9. https://doi.org/10.1001/jama.297.18.2001
  5. Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J 2008;72:56-60. https://doi.org/10.1253/circj.72.56
  6. Goel SS, Dilip Gajulapalli R, Athappan G, et al. Management of drug eluting stent in-stent restenosis: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2016;87:1080-91. https://doi.org/10.1002/ccd.26151
  7. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897-907. https://doi.org/10.1016/j.jacc.2010.07.028
  8. Solinas E, Dangas G, Kirtane AJ, et al. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. Am J Cardiol 2008;102:311-5. https://doi.org/10.1016/j.amjcard.2008.03.060
  9. Alfonso F, Cequier A, Angel J, et al. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. Am Heart J 2006;151:681.e1-681.e9. https://doi.org/10.1016/j.ahj.2005.10.014
  10. Alfonso F. Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis? J Am Coll Cardiol 2010;55:2717-20. https://doi.org/10.1016/j.jacc.2010.03.026
  11. Byrne RA, Joner M, Tada T, Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. Minerva Cardioangiol 2012;60:473-89.
  12. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-6. https://doi.org/10.1056/NEJM199602293340903
  13. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9. https://doi.org/10.1016/j.jcin.2008.11.015
  14. Collet CA, Costa JR, Abizaid A, et al. Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents. JACC Cardiovasc Interv 2011;4:1067-74.
  15. Alfonso F, Perez-Vizcayno MJ, Cruz A, et al. Treatment of patients with in-stent restenosis. EuroIntervention 2009;5 Suppl D:D70-8.
  16. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22. https://doi.org/10.1016/j.jacc.2011.01.011
  17. Fujii K, Mintz GS, Kobayashi Y, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation 2004;109:1085-8. https://doi.org/10.1161/01.CIR.0000121327.67756.19
  18. Alfonso F, Sandoval J, Cardenas A, Medina M, Cuevas C, Gonzalo N. Optical coherence tomography: from research to clinical application. Minerva Med 2012;103:441-64.
  19. Angiolillo DJ, Sabata M, Alfonso F, Macaya C. "Candy wrapper" effect after drug-eluting stent implantation: deja vu or stumbling over the same stone again? Catheter Cardiovasc Interv 2004;61:387-91. https://doi.org/10.1002/ccd.10765
  20. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation 2011;123:2954-63. https://doi.org/10.1161/CIRCULATIONAHA.110.988436
  21. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart 2014;100:153-9. https://doi.org/10.1136/heartjnl-2013-304933
  22. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 2011;4:149-54. https://doi.org/10.1016/j.jcin.2010.10.012
  23. Nicolais C, Lakhter V, Virk HU, et al. Therapeutic options for in-stent restenosis. Curr Cardiol Rep 2018;20:7. https://doi.org/10.1007/s11886-018-0952-4
  24. Hernandez RA, Macaya C, Iniguez A, et al. Midterm outcome of patients with asymptomatic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1992;19:1402-9. https://doi.org/10.1016/0735-1097(92)90594-D
  25. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:32-6. https://doi.org/10.1016/j.jacc.2006.02.060
  26. Kim YH, Her AY, Rha SW, et al. Routine angiographic follow-up versus clinical follow-up after percutaneous coronary intervention in acute myocardial infarction. Yonsei Med J 2017;58:720-30. https://doi.org/10.3349/ymj.2017.58.4.720
  27. Kim YH, Her AY, Rha SW, et al. Routine angiographic follow-up versus clinical follow-up in patients with multivessel coronary artery diseases following percutaneous coronary intervention with drug-eluting stents: a nested case-control study within a Korean population. Coron Artery Dis 2017;28:307-14. https://doi.org/10.1097/MCA.0000000000000479
  28. Lopez-Palop R, Pinar E, Lozano I, Saura D, Pico F, Valdes M. Utility of the fractional flow reserve in the evaluation of angiographically moderate in-stent restenosis. Eur Heart J 2004;25:2040-7. https://doi.org/10.1016/j.ehj.2004.07.016
  29. Nam CW, Rha SW, Koo BK, et al. Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. Am J Cardiol 2011;107:1783-6. https://doi.org/10.1016/j.amjcard.2011.02.328
  30. Mukherjee D, Reginelli JP, Moliterno DJ, et al. Unexpected mortality reduction with abciximab for in-stent restenosis. J Invasive Cardiol 2000;12:540-4.
  31. Moustapha A, Assali AR, Sdringola S, et al. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis. Catheter Cardiovasc Interv 2002;56:184-7. https://doi.org/10.1002/ccd.10166
  32. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110:790-5. https://doi.org/10.1161/01.CIR.0000138935.17503.35
  33. Kufner S, Hausleiter J, Ndrepepa G, et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv 2009;2:1142-8. https://doi.org/10.1016/j.jcin.2009.08.015
  34. Macander PJ, Roubin GS, Agrawal SK, Cannon AD, Dean LS, Baxley WA. Balloon angioplasty for treatment of in-stent restenosis: feasibility, safety, and efficacy. Cathet Cardiovasc Diagn 1994;32:125-31. https://doi.org/10.1002/ccd.1810320206
  35. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol 2014;63:2659-73. https://doi.org/10.1016/j.jacc.2014.02.545
  36. Alfonso F, Perez-Vizcayno MJ, Hernandez R, et al. Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis. Am J Cardiol 1999;83:1268-70, A9. https://doi.org/10.1016/S0002-9149(99)00071-5
  37. Mehran R, Mintz GS, Popma JJ, et al. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996;78:618-22. https://doi.org/10.1016/S0002-9149(96)00381-5
  38. Alfonso F, Garcia P, Fleites H, et al. Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis. Angiographic and intravascular ultrasound findings of a randomized study. Am Heart J 2005;149:e1-8.
  39. Alfonso F, Perez-Vizcayno MJ, Gomez-Recio M, et al. Implications of the "watermelon seeding" phenomenon during coronary interventions for in-stent restenosis. Catheter Cardiovasc Interv 2005;66:521-7. https://doi.org/10.1002/ccd.20524
  40. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013;381:461-7. https://doi.org/10.1016/S0140-6736(12)61964-3
  41. Montorsi P, Galli S, Fabbiocchi F, Trabattoni D, Ravagnani PM, Bartorelli AL. Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up. Ital Heart J 2004;5:271-9.
  42. Adamian M, Colombo A, Briguori C, et al. Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol 2001;38:672-9. https://doi.org/10.1016/S0735-1097(01)01458-9
  43. Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). J Am Coll Cardiol 2004;43:943-9. https://doi.org/10.1016/j.jacc.2003.09.054
  44. Kufner S, Joner M, Schneider S, et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Interv 2017;10:1332-40. https://doi.org/10.1016/j.jcin.2017.04.024
  45. Mehran R, Dangas G, Mintz GS, et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation 2000;101:2484-9. https://doi.org/10.1161/01.CIR.101.21.2484
  46. Sanchez PL, Rodriguez-Alemparte M, Colon-Hernandez PJ, et al. Directional coronary atherectomy vs. rotational atherectomy for the treatment of in-stent restenosis of native coronary arteries. Catheter Cardiovasc Interv 2003;58:155-61. https://doi.org/10.1002/ccd.10399
  47. Sharma SK, Kini A, Mehran R, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of rotational atherectomy versus balloon angioplasty for diffuse in-stent restenosis (ROSTER). Am Heart J 2004;147:16-22. https://doi.org/10.1016/j.ahj.2003.07.002
  48. vom Dahl J, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation 2002;105:583-8. https://doi.org/10.1161/hc0502.103347
  49. Ichimoto E, Kadohira T, Nakayama T, De Gregorio J. Long-term clinical outcomes after treatment with excimer laser coronary atherectomy for in-stent restenosis of drug-eluting stent. Int Heart J 2018;59:14-20. https://doi.org/10.1536/ihj.16-638
  50. Kobayashi Y, Teirstein P, Linnemeier T, Stone G, Leon M, Moses J. Rotational atherectomy (stentablation) in a lesion with stent underexpansion due to heavily calcified plaque. Catheter Cardiovasc Interv 2001;52:208-11. https://doi.org/10.1002/1522-726X(200102)52:2<208::AID-CCD1049>3.0.CO;2-H
  51. Alfonso F, Sandoval J, Nolte C. Calcified in-stent restenosis: a rare cause of dilation failure requiring rotational atherectomy. Circ Cardiovasc Interv 2012;5:e1-2. https://doi.org/10.1161/CIRCINTERVENTIONS.111.966606
  52. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-6. https://doi.org/10.1056/NEJM200101253440402
  53. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000;101:2165-71. https://doi.org/10.1161/01.CIR.101.18.2165
  54. Holmes DR Jr, Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006;295:1264-73. https://doi.org/10.1001/jama.295.11.1264
  55. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006;295:1253-63. https://doi.org/10.1001/jama.295.11.1253
  56. Torguson R, Sabate M, Deible R, et al. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol 2006;98:1340-4. https://doi.org/10.1016/j.amjcard.2006.06.027
  57. Mintz GS, Hoffmann R, Mehran R, et al. In-stent restenosis: the Washington Hospital Center experience. Am J Cardiol 1998;81:7E-13E. https://doi.org/10.1016/S0002-9149(98)00190-8
  58. Alfonso F, Zueco J, Cequier A, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003;42:796-805. https://doi.org/10.1016/S0735-1097(03)00852-0
  59. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65. https://doi.org/10.1056/NEJMra1210816
  60. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48. https://doi.org/10.1016/S0140-6736(07)61444-5
  61. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
  62. Dibra A, Kastrati A, Alfonso F, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007;49:616-23. https://doi.org/10.1016/j.jacc.2006.10.049
  63. Alfonso F, Perez-Vizcayno MJ, Hernandez R, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon angioplasty versus elective sirolimus-eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006;47:2152-60. https://doi.org/10.1016/j.jacc.2005.10.078
  64. Alfonso F, Perez-Vizcayno MJ, Hernandez R, et al. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol 2008;52:1621-7. https://doi.org/10.1016/j.jacc.2008.08.025
  65. Byrne RA, Cassese S, Windisch T, et al. Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. EuroIntervention 2013;9:797-802. https://doi.org/10.4244/EIJV9I7A132
  66. Latib A, Mussardo M, Ielasi A, et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv 2011;4:155-64.
  67. Kastrati A, Byrne R. New roads, new ruts: lessons from drug-eluting stent restenosis. JACC Cardiovasc Interv 2011;4:165-7. https://doi.org/10.1016/j.jcin.2010.11.008
  68. Alfonso F, Perez-Vizcayno MJ, Dutary J, et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-stent: Balloon angioplasty versus drug-eluting Stent]). JACC Cardiovasc Interv 2012;5:728-37. https://doi.org/10.1016/j.jcin.2012.03.017
  69. Alfonso F, Garcia J, Perez-Vizcayno MJ, et al. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. J Am Coll Cardiol 2009;54:1036-8. https://doi.org/10.1016/j.jacc.2009.04.082
  70. Rivero F, Bastante T, Cuesta J, Benedicto A, Restrepo JA, Alfonso F. Treatment of in-stent restenosis with bioresorbable vascular scaffolds: optical coherence tomography insights. Can J Cardiol 2015;31:255-9. https://doi.org/10.1016/j.cjca.2014.11.017
  71. Jamshidi P, Nyffenegger T, Sabti Z, et al. A novel approach to treat in-stent restenosis: 6-and 12-month results using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention 2016;11:1479-86. https://doi.org/10.4244/EIJV11I13A287
  72. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24. https://doi.org/10.1056/NEJMoa061254
  73. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986-94. https://doi.org/10.1161/CIRCULATIONAHA.108.839282
  74. Alfonso F, Perez-Vizcayno MJ, Cardenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol 2014;63:1378-86. https://doi.org/10.1016/j.jacc.2013.12.006
  75. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 2012;59:1377-82. https://doi.org/10.1016/j.jacc.2012.01.015
  76. Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv 2014;7:204-11.
  77. Indermuehle A, Bahl R, Lansky AJ, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart 2013;99:327-33. https://doi.org/10.1136/heartjnl-2012-302945
  78. Alfonso F, Perez-Vizcayno MJ, Cardenas A, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol 2015;66:23-33. https://doi.org/10.1016/j.jacc.2015.04.063
  79. Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015;386:655-64. https://doi.org/10.1016/S0140-6736(15)60657-2
  80. Giacoppo D, Gargiulo G, Aruta P, Capranzano P, Tamburino C, Capodanno D. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ 2015;351:h5392.

Cited by

  1. Koronare Restenose vol.44, pp.1, 2018, https://doi.org/10.1007/s00059-018-4777-0
  2. MicroRNAs: New Biomarkers for the progression of Coronary Artery Diseases vol.185, pp.None, 2018, https://doi.org/10.1051/e3sconf/202018503039
  3. Clinical profile and angiographic patterns of patients undergoing treatment for in-stent restenosis and outcomes associated with the treatment vol.9, pp.3, 2018, https://doi.org/10.4103/rcm.rcm_21_20
  4. Effect of Intravascular Ultrasound–Guided Drug-Eluting Stent Implantation : 5-Year Follow-Up of the IVUS-XPL Randomized Trial vol.13, pp.1, 2020, https://doi.org/10.1016/j.jcin.2019.09.033
  5. Prediabetes predicts adverse cardiovascular outcomes after percutaneous coronary intervention: a meta-analysis vol.40, pp.1, 2018, https://doi.org/10.1042/bsr20193130
  6. Drug-eluting balloon: is it useful? vol.72, pp.1, 2020, https://doi.org/10.1186/s43044-020-00116-7
  7. Predictive value of inflammatory factors on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease : A protocol for systematic review and meta-analysis vol.100, pp.13, 2018, https://doi.org/10.1097/md.0000000000025356
  8. Intracoronary brachytherapy for the treatment of recurrent drug-eluting stent in-stent restenosis: A systematic review and meta-analysis vol.13, pp.4, 2018, https://doi.org/10.4330/wjc.v13.i4.95
  9. Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy vol.5, pp.2, 2018, https://doi.org/10.1063/5.0037298
  10. Risk factors associated with intra‑stent restenosis after percutaneous coronary intervention vol.22, pp.4, 2021, https://doi.org/10.3892/etm.2021.10575
  11. Impact of chronic kidney disease on long-term outcomes for coronary in-stent restenosis after drug-coated balloon angioplasty vol.78, pp.6, 2021, https://doi.org/10.1016/j.jjcc.2021.08.010